METHODS OF MONITORING SPLICING

The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PICKERING, Raelene Jane, THOMAS, Merlin Christopher
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	PICKERING, Raelene Jane THOMAS, Merlin Christopher
description	The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject. La présente invention concerne des procédés d'identification de l'épissage de pré-ARNm RAGE conduisant à l'inclusion de l'exon 9b et/ou l'exclusion de l'exon 10 chez un sujet qui a reçu, ou qui reçoit, un oligonucléotide antisens qui module l'épissage de pré-ARNm RAGE. Selon un aspect, la présente invention propose un procédé de détermination d'un récepteur soluble endogène pour un niveau de produits finaux de glycation avancée (RAGE) dans le poumon d'un sujet, le procédé consistant à : déterminer la présence de RAGE soluble endogène dans un échantillon de sang provenant d'un sujet qui a reçu ou qui reçoit un traitement administré à ses voies respiratoires, le traitement augmentant la quantité de RAGE soluble endogène, le niveau de RAGE soluble endogène dans l'échantillon de sang étant en corrélation avec le niveau de RAGE soluble endogène dans le poumon du sujet.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024229514A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024229514A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024229514A13</originalsourceid><addsrcrecordid>eNrjZJDzdQ3x8HcJVvB3U_D19_MM8Q_y9HNXCA7w8XQGMngYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmRkaWpoYmjoTFxqgBB_SJb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS OF MONITORING SPLICING</title><source>esp@cenet</source><creator>PICKERING, Raelene Jane ; THOMAS, Merlin Christopher</creator><creatorcontrib>PICKERING, Raelene Jane ; THOMAS, Merlin Christopher</creatorcontrib><description>The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject. La présente invention concerne des procédés d'identification de l'épissage de pré-ARNm RAGE conduisant à l'inclusion de l'exon 9b et/ou l'exclusion de l'exon 10 chez un sujet qui a reçu, ou qui reçoit, un oligonucléotide antisens qui module l'épissage de pré-ARNm RAGE. Selon un aspect, la présente invention propose un procédé de détermination d'un récepteur soluble endogène pour un niveau de produits finaux de glycation avancée (RAGE) dans le poumon d'un sujet, le procédé consistant à : déterminer la présence de RAGE soluble endogène dans un échantillon de sang provenant d'un sujet qui a reçu ou qui reçoit un traitement administré à ses voies respiratoires, le traitement augmentant la quantité de RAGE soluble endogène, le niveau de RAGE soluble endogène dans l'échantillon de sang étant en corrélation avec le niveau de RAGE soluble endogène dans le poumon du sujet.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PHYSICS ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241114&DB=EPODOC&CC=WO&NR=2024229514A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241114&DB=EPODOC&CC=WO&NR=2024229514A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PICKERING, Raelene Jane</creatorcontrib><creatorcontrib>THOMAS, Merlin Christopher</creatorcontrib><title>METHODS OF MONITORING SPLICING</title><description>The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject. La présente invention concerne des procédés d'identification de l'épissage de pré-ARNm RAGE conduisant à l'inclusion de l'exon 9b et/ou l'exclusion de l'exon 10 chez un sujet qui a reçu, ou qui reçoit, un oligonucléotide antisens qui module l'épissage de pré-ARNm RAGE. Selon un aspect, la présente invention propose un procédé de détermination d'un récepteur soluble endogène pour un niveau de produits finaux de glycation avancée (RAGE) dans le poumon d'un sujet, le procédé consistant à : déterminer la présence de RAGE soluble endogène dans un échantillon de sang provenant d'un sujet qui a reçu ou qui reçoit un traitement administré à ses voies respiratoires, le traitement augmentant la quantité de RAGE soluble endogène, le niveau de RAGE soluble endogène dans l'échantillon de sang étant en corrélation avec le niveau de RAGE soluble endogène dans le poumon du sujet.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PHYSICS</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJDzdQ3x8HcJVvB3U_D19_MM8Q_y9HNXCA7w8XQGMngYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmRkaWpoYmjoTFxqgBB_SJb</recordid><startdate>20241114</startdate><enddate>20241114</enddate><creator>PICKERING, Raelene Jane</creator><creator>THOMAS, Merlin Christopher</creator><scope>EVB</scope></search><sort><creationdate>20241114</creationdate><title>METHODS OF MONITORING SPLICING</title><author>PICKERING, Raelene Jane ; THOMAS, Merlin Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024229514A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PHYSICS</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>PICKERING, Raelene Jane</creatorcontrib><creatorcontrib>THOMAS, Merlin Christopher</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PICKERING, Raelene Jane</au><au>THOMAS, Merlin Christopher</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS OF MONITORING SPLICING</title><date>2024-11-14</date><risdate>2024</risdate><abstract>The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject. La présente invention concerne des procédés d'identification de l'épissage de pré-ARNm RAGE conduisant à l'inclusion de l'exon 9b et/ou l'exclusion de l'exon 10 chez un sujet qui a reçu, ou qui reçoit, un oligonucléotide antisens qui module l'épissage de pré-ARNm RAGE. Selon un aspect, la présente invention propose un procédé de détermination d'un récepteur soluble endogène pour un niveau de produits finaux de glycation avancée (RAGE) dans le poumon d'un sujet, le procédé consistant à : déterminer la présence de RAGE soluble endogène dans un échantillon de sang provenant d'un sujet qui a reçu ou qui reçoit un traitement administré à ses voies respiratoires, le traitement augmentant la quantité de RAGE soluble endogène, le niveau de RAGE soluble endogène dans l'échantillon de sang étant en corrélation avec le niveau de RAGE soluble endogène dans le poumon du sujet.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre
recordid	cdi_epo_espacenet_WO2024229514A1
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
title	METHODS OF MONITORING SPLICING
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PICKERING,%20Raelene%20Jane&rft.date=2024-11-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024229514A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true